Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Overig’

‘Europese regels nodig over transparantie banden zorg en farma’

Het openbaar maken van financiële banden tussen zorgverleners en de farmaceutische industrie in Europa kan beter. Ook in Nederland is er nog onvoldoende transparantie, concluderen onderzoekers van universiteiten in Zweden, Letland en Australië en Health Action International (HAI) in een studie waarover het Nederland Tijdschrift voor Geneeskunde (NTvG) bericht. Ze pleiten voor Europese regelgeving.

Bron: Skipr Meer lezen »

CBG lanceert patiëntenfolder over gebruik van biologische medicijnen

Biologische medicijnen spelen een steeds grotere rol bij de behandeling van diverse aandoeningen. Ook krijgen patiënten mogelijk te maken met een overstap naar andere, soortgelijke biologische medicijnen: biosimilars.

Bron: Medicalfacts Meer lezen »

Roche’s immunotherapy lucky streak ends with deaths in trial

Roche’s Tecentriq had begun to show signs of reviving its hopes in the competitive PD-1/L1 market, succeeding in two Phase 3 trials in lung cancer and receiving a NICE approval.

Bron: Pharmafile Meer lezen »

Abbvie’s rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3

Abbvie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own best-selling blockbuster Humira (adalimumab) at Phase 3 in the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to methotrexate, hitting both its primary and secondary endpoints.

Bron: Pharmafile Meer lezen »

Sobi receives expanded EU approval for Kineret

Joining its current indication as a treatment for rheumatoid arthritis and cryopyrin-associated periodic syndromes, Sobi’s Kineret has been given approval by the European Commission to include an indication for Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease.

Bron: Pharmafile Meer lezen »

Shire dropped oncology unit for $2.4bn, unbalancing Takeda deal

Shire has announced that it has entered a definitive agreement for French drugmaker Servier to take on its oncology business.

Bron: Pharmafile Meer lezen »

Keytruda continues success with new Phase 3 data in adjuvant melanoma

MSD has revealed new efficacy data for Keytruda (permbrolizumab) as an adjuvant therapy in the treatment of resected, high-risk stage III melanoma. It is the third such reveal in weeks, following the drug’s success as a monotherapy in NSCLC with any PD-L1 expression but failure as a combo therapy in unresectable or metastatic melanoma.

Bron: Pharmafile Meer lezen »

GSK inks agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics

GSK, a science─led global healthcare company, and Orchard Therapeutics, a privately held clinical─stage biotechnology company, both jointly announced a strategic agreement.

Bron: Pharma Biz Meer lezen »

EMA announces second-ever public hearing on high-use antibiotics

The EMA has announced, following the first-ever public hearing on valproate, that it would hold a second public hearing regarding the use of quinolone and fluoroquinolone antibiotics.  

Bron: Pharmafile Meer lezen »

Sanofi to invest €350m in new Canadian vaccine plant

Sanofi has announced plans to spend €350 million on a new vaccine facility located in Toronto, Canada, a move which, according to the company, is one of its biggest-ever investments in a single building.  

Bron: Pharmafile Meer lezen »

« Oudere artikelen |